Could an Immune-Suppressing drug treat some forms of schizophrenia?
NCT ID NCT03971487
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether ocrelizumab, a drug that suppresses certain immune cells, can reduce psychosis symptoms in people whose schizophrenia or bipolar disorder may be caused by auto-antibodies attacking brain receptors. Forty participants aged 18–35 will receive either ocrelizumab or a placebo, and their symptoms will be measured using standard psychiatric scales. The goal is to see if targeting the immune system can improve outcomes for this specific subgroup.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ocrelizumab
What this could lead to
If it works, this could point toward a new treatment for some people with schizophrenia or bipolar disorder whose illness is caused by auto-antibodies attacking the brain.
What could go wrong
This is an early-phase trial with only 40 people, so results may not apply to everyone. Ocrelizumab suppresses the immune system, which can increase infection risk, and it is not yet proven to help psychosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Research Institute
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••